Beruflich Dokumente
Kultur Dokumente
Cancer is a disease in which there uncontrolled multiplication and spread within the body of abnormal forms of the body owns cells. The terms cancer and malignant tumor are synonymous, and are distinguished from benign tumors by the properties of uncontrolled proliferation, dedifferentiation, invasiveness and the ability to metastasize (spread to other parts of body).
The proliferation of cancer cells is not controlled by the processes that normally regulate cell division and
Cancer cells loss of the capacity to differentiate. In general, poorly differentiated cancers multiply faster, and have a poorer prognosis than well-differentiated cancers.
Cancer cells secrete enzymes, e.g. metalloproteinases, that break down the extracellular matrix enabling the cancer cells to slip through. Expansion of the tumour requires the development of new blood vessels - angiogenesis, which occurs in response to vascular growth factors produced by the growing tumor. During angiogenesis, enzymes (e.g. metalloproteinases) break down surrounding tissue -
These are secondary tumors formed by cells that have been released from the initial or primary tumor and have reached other sites through blood vessels or lymphatics. The aberrant migration of cells would lead to programmed cell death as a result of withdrawal of the necessary anti-apoptotic factors. Cancer cells which have the ability to metastasise, have undergone a series of genetic changes which alter their responses to the regulatory factors that control the tissue siting of normal cells.
Activation of proto-oncogenes
The host's genes that control normal growth and differentiation - the 'proto-
viruses.
Oncogenes interfere not only with proliferation but also with differentiation - inducing defects in the execution of differentiation programmes. And it may well be that one of the fundamental effects of oncogene products is to interfere with the action of tumour suppressor genes.
9
Chemotherapy of tumors are necessarily aimed at producing as near a total cell kill as possible
Chemotherapy is the main method of treatment for only a few cancers but it is increasingly used as an adjunct to surgery or irradiation for many types of tumor
Other approaches:
immunotherapy gene therapy use of biological response modifiers (e.g. interferons, haemopoietic growth factors, etc.)
10
Most currently used anticancer drugs, in particular those which are 'cytotoxic', affect only the first of the characteristics of cancer cells outlined previously - the process of cell division, i.e. they are anti-proliferative; they have no specific inhibitory effect on invasiveness, the loss of differentiation or the tendency to metastasize. Because their main effect is on cell division, they will affect all rapidly dividing normal tissues and thus they are likely to produce the general toxic effects (bone marrow toxicity, impaired wound healing, loss of hair (alopecia), damage to gastrointestinal epithelium, depression of growth in children, sterility, teratogenicity, kidney damage, severe nausea and vomiting).
11
G0 G1
The cells of a solid tumor can be considered as belonging to three compartments: - compartment A - consists of dividing cells, possibly being continuously in cell cycle; - compartment consists of resting cells (in G0 phase) cells which, though not dividing, are potentially able to do so; - compartment consists of cells that are no longer able to divide but which contribute to the tumor volume.
12
The cells in compartment do not constitute a problem - it is the existence of cells in compartment that makes cancer chemotherapy difficult, because these cells are not very sensitive to cytotoxic drugs, but are liable to re-enter compartment A following a
course of chemotherapy.
13
14
For tumors with a small growth fraction the use of cycle non-specific agents (together with surgery or Xray) could be considered
15
Decreased accumulation of drugs in cells due to the increased expression of a cell surface, drug transport protein, termed Pglycoprotein (doxorubicin, vinblastine, etc.) Insufficient activation of the drug (mercaptopurine, fluorouracil, cytarabine) Increased concentration of target enzyme (methotrexate) Decreased requirement for substrate (L-asparaginase) Increased utilization of alternative metabolic pathways (antimetabolites) Rapid repair of drug-induced lesions (alkylating agents). Altered activity of target, for example modified topoisomerase II (doxorubicin)
16
17
Folate antagonists: Methotrexate Purine analogues: 6-Mercaptopurine, Fludarabine Pyrimidine analogues: 5-Fluorouracil
18
IV. Plant derivatives: Vinca alkaloids: Vincristine, Vinblastine Taxanes: Paclitaxel, Docetaxel Podophyllotoxins: Teniposide, Etoposide Camptothecins: Topotecan, Irinotecan Alcaloids of Colchicine: Colchamine V. Enzymes: L-Asparaginase
19
20
21
Inhibitors of metallo-proteinases These enzymes are involved in both the invasiveness and metastasis of cancer. Marimastat and others are the agents that inhibit these enzymes. Other angiogenesis inhibitors include an analogue of fumagillin (a fungal product), IL-2 and a calciumchannel blocker. Differentiation inductors Agents that can block the proliferation of cancer cells and induce their differentiation
23
Oligonucleotides (ONs) Small synthetic segments of single-stranded DNA that are complementary to a portion of the mRNA and which can bind to their corresponding sequence on the mRNA. This now double-stranded section - a hybrid of mRNA and ON DNA - prevents translation of the mRNA and thus blocks expression of the particular oncogene. Agents enhancing the chemo- and radio-sensitivity of tumor cells Anti-metastatics Decrease adhesion of cancer cells in the tissue and prevent metastases formation
24
Alkylating agents have alkyl groups which can form covalent bonds with cell substituents; a carbonium ion is the reactive intermediate. Most have two alkylating groups and can cross-link two nucleophilic sites such as the N7 of guanine in DNA. Cross-linking can cause defective replication due to pairing of alkylguanine with thymine leading to substitution of AT for GC, or excision of guanine and chain breakage. Their principal effect occurs during DNA synthesis; the resulting DNA damage triggers apoptosis. Unwanted effects include myelosuppression, sterility and risk of nonlymphocytic leukaemia. The main alkylating agents are:
Nitrogen mustards: e.g. cyclophosphamide, which is activated to give aldophosphamide, which is then converted to phosphoramide mustard (the cytotoxic molecule) and acrolein (which causes bladder damage that can be ameliorated by mesna). Cyclophosphamide myelosuppression affects particularly the lymphocytes. Nitrosoureas: e.g. lomustine may act on non-dividing cells; can cross the blood-brain barrier; causes delayed, cumulative myelotoxicity. Cisplatin causes intrastrand linking in DNA; it has low myelotoxicity but causes severe nausea and vomiting and can be nephrotoxic. It has revolutionised the treatment of germ cell tumours.
25
Antimetabolites
Methotrexate inhibits dihydrofolate reductase, preventing generation of tetrahydrofolate; the main result is interference with thymidylate synthesis. Methotrexate is taken up into cells by the folate carrier, and, like folate, converted to the polyglutamate form. Unwanted effects: myelosuppression, possible nephratoxicity.
Fluorouracil is converted to a fraudulent nucleotide and inhibits thymidylate synthesis. Cytarabine its triphosphate form inhibits DNA polymerase; potent myelosuppressive. Mercaptopurine is converted into a fraudulent nucleotide. Fludarabine its triphosphate form inhibits DNA polymerase; it is myelosuppressive.
Pyrimidine analogues
Purine analogues
26
Cytotoxic antibiotics
Doxorubicin inhibits DNA and RNA synthesis; the DNA effect is mainly due to interference with topoisomerase II action. Unwanted effects: nausea and vomiting, myelosuppression, hair loss; it is cardiotoxic in high doses. Bleomycin causes fragmentation of DNA chains. It can act on non-dividing cells. Unwanted effects: fever, allergies, mucocutaneous reactions, pulmonary fibrosis. Virtually no myelosuppression. Dactinomycin intercalates in DNA, interfering with RNApolymerase and inhibiting transcription. It also interferes with the action of topoisomerase II. Unwanted effects: nausea and vomiting, myelosuppression. Mitomycin is activated to give an alkylating metabolite.
27
Plant derivatives
Vinca alkaloids
Vincristine inhibits mitosis at metaphase by binding to tubulin. Relatively non-toxic, but can cause unwanted neuromuscular effects. Etoposide inhibits DNA synthesis by an action on topoisomerase II, and also inhibits mitochondrial function. Common unwanted effects include vomiting, myelosuppression and alopecia. Paclitaxel stabilises microtubules, inhibiting mitosis; relatively toxic, hypersensitivity reactions occur. Irinotecan binds to and inhibits topoisomerase 1; relatively few toxic effects.
Podophyllotoxins
Taxones
Campothecins
28
Hormones or their antagonists are used in hormonesensitive tumours: Glucocorticoids for leukaemias and lymphomas Oestrogens for treatment androgen-dependent prostatic tumours and mammary cancer (during menopause) Progestogens for treatment endometrial neoplasms and renal tumours Gonadotropin releasing hormone analogues for prostate and breast tumours Analogue of somatostatin, octreotide for treatment various hormone-secreting tumours of the gastrointestinal tract Anti-oestrogens (tamoxifen) for breast tumours Antiandrogens (flutamide, cyproterone) for prostate cancers Aromatase inhibitors - inhibitors of sex hormone synthesis (aminoglutethimide) for postmenopausal breast cancer.
29